So at ASCO 2026, I was giving an update on the controversy about utilization of genomic assays in patients who have node-positive, hormone-receptor-positive disease. So in this talk, we discuss the data from RxPONDER . We talk about the data from the MINDACT study. We talk about the ASCO-CAP guidelines, which were last updated in 2022. But then at this meeting, we saw the data from the OPTIMA study, which looked at patients who were greater than or equal to age 40, utilized the PAM50 assay, had a different design than the other studies where it was test-direct versus a control arm and showed this was for patients with N0 to N2 disease...
So at ASCO 2026, I was giving an update on the controversy about utilization of genomic assays in patients who have node-positive, hormone-receptor-positive disease. So in this talk, we discuss the data from RxPONDER . We talk about the data from the MINDACT study. We talk about the ASCO-CAP guidelines, which were last updated in 2022. But then at this meeting, we saw the data from the OPTIMA study, which looked at patients who were greater than or equal to age 40, utilized the PAM50 assay, had a different design than the other studies where it was test-direct versus a control arm and showed this was for patients with N0 to N2 disease. And, you know, talk about the implications now. Now we have evidence of PAM50, including in premenopausal women. And it is worth noting that the Optima study mandated that patients undergo ovarian function suppression for at least three years as opposed to the other trials. And so there are some evidence now in that population with a genomic score, again, for patients greater than or equal to 40 years of age, that if you do ovarian function suppression and aromatase inhibition or endocrine therapy, that you might not need chemotherapy. And so we contextualize this just given that the field with genomic assays continues to evolve.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
